



Explore Our Active Clinical Trials*


Tap on a trial to learn more


Investigating Established Agents in New Treatment Areas or Settings


BRENTUXIMAB VEDOTIN^a


 **3**


 Diffuse large B-cell lymphoma
ECHELON-3 | 3L+


 **2**


 Hodgkin lymphoma and CD30+ peripheral T-cell lymphoma
SGN35-015 | 1L


 **2**


 Early and advanced stage Hodgkin lymphoma
SGN35-027 | 1L


 **2**

 CD30-low and -negative peripheral T-cell lymphoma
SGN35-032 | 1L


 **2**


 Metastatic non-small-cell lung cancer and melanoma
SGN35-033 | 1L, 2L


 **2**


 AYA CD30+ Hodgkin lymphoma
CHECKMATE 744 | 2L


ENFORTUMAB VEDOTIN^b


 **3**


 Locally advanced or metastatic urothelial cancer
EV-302/KEYNOTE-A39^c | 1L


 **3**


 Cisplatin-ineligible/decline muscle-invasive bladder cancer
KEYNOTE-905/EV-303^d | Perioperative


 **3**


 Cisplatin-eligible muscle-invasive bladder cancer
KEYNOTE-B15/EV-304^d | Perioperative


 **2**

 Locally advanced or metastatic solid tumors
EV-202 | 2L+





 **1b/2**

 Urothelial cancer
EV-103/KEYNOTE-869^c | Various settings

 **1**

 BCG-unresponsive non-muscle-invasive bladder cancer
EV-104 | Intravesical EV

Seagen Technology

-  Antibody-drug conjugate (ADC)
-  Sugar-engineered antibody (SEA)
-  Small molecule
-  Bispecific antibody

Trial phase



Line of therapy

- 1L:** first line
- 2L:** second line
- 3L:** third line

*The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

^aProgram being developed in collaboration with Takeda Pharmaceutical Company, Ltd.; ^bProgram being co-developed with Astellas Pharma Global Development, Inc.; ^cStudy sponsored by Astellas Pharma Global Development, Inc., in collaboration with Seagen Inc. and Merck Sharp & Dohme LLC; ^dStudy sponsored by Merck Sharp & Dohme LLC, in collaboration with Seagen Inc. and Astellas Pharma Global Development, Inc.

Explore Our Active Clinical Trials*

Tap on a trial to learn more

Investigating Established Agents in New Treatment Areas or Settings (continued)

TUCATINIB

HER2+ breast cancer
CompassHER2 RD^e | EBC

HER2+ breast cancer
HER2CLIMB-02 | 2L

HER2+ breast cancer
HER2CLIMB-05ⁱ | 1L

HER2+ colorectal cancer
MOUNTAINEER-03^f | 1L

HER2+ breast cancer
HER2CLIMB-04 | 2L+

Locally advanced or metastatic solid tumors with HER2 alterations
SGTUC-019 | 2L+

HER2+ gastrointestinal cancers
SGTUC-024 | 1L+

TISOTUMAB VEDOTIN^g

Recurrent or metastatic cervical cancer
innovaTV 301 | 2L/3L

Recurrent or metastatic cervical cancer
innovaTV 205^h | 1L, 2L/3L

Advanced solid tumors
innovaTV 207^h | 1L, 2L+

Seagen Technology

- Antibody-drug conjugate (ADC)
- Sugar-engineered antibody (SEA)
- Small molecule
- Bispecific antibody

Trial phase



Line of therapy

- 1L: first line
- 2L: second line
- 3L: third line

*The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

EBC: early breast cancer; **HER2:** human epidermal growth factor receptor 2


^eTrial being conducted by the Alliance for Clinical Trials in Oncology; ⁱTrial being co-developed with Merck Sharp & Dohme LLC; ^gProgram being co-developed with Genmab A/S; ^hProgram being co-developed with Merck Sharp & Dohme LLC

Explore Our Active Clinical Trials*


Tap on a trial to learn more

Late-Stage ADCs


DISITAMAB VEDOTIN



LADIRATUZUMAB VEDOTIN^h




1b/2


 Triple-negative breast cancer
SGNLVA-002/KEYNOTE-721 | 1L

Early-Stage ADCs


SGN-ALPV




SGN-B6A




SGN-B7H4V







SGN-PDL1V



SGN-STNV



Seagen Technology

-  Antibody-drug conjugate (ADC)
-  Sugar-engineered antibody (SEA)
-  Small molecule
-  Bispecific antibody

Trial phase



Line of therapy

- 1L:** first line
- 2L:** second line
- 3L:** third line

*The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

HER2: human epidermal growth factor receptor 2

[†]Program being co-developed with Merck Sharp & Dohme LLC; ^hTrial in collaboration with RemeGen Co., Ltd. and Merck Sharp & Dohme LLC

Explore Our Active Clinical Trials*

Tap on a trial to learn more

Other Targeted Modalities

SGN-BB228

1



Advanced melanoma and other solid tumors

SGNBB228-001 | 2L+

SEA-CD70

1



Myelodysplastic syndrome and acute myeloid leukemia

SGNS70-101 | 1L+

SEA-TGT

1



Advanced solid tumors and lymphomas

SGNTGT-001 | 1L/1L+

Seagen Technology



Antibody-drug conjugate (ADC)



Sugar-engineered antibody (SEA)



Small molecule



Bispecific antibody

Trial phase



Line of therapy

1L: first line

2L: second line

3L: third line

*The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.